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Abstract: Objectives To evaluate the association of short-term neurological improvement until day of
life 4 in neonates with hypoxic-ischemic encephalopathy (HIE) receiving therapeutic hypothermia (TH)
with neurodevelopmental outcome at 18-24 months. Methods This is a retrospective analysis of prospec-
tively collected data of 174 neonates with HIE registered in the Swiss National Asphyxia and Cooling
Register between 2011 and 2013. TH was initiated according to national guidelines, and Sarnat staging
was performed daily. Short-term neurological improvement was defined if Sarnat stage improved from
admission until day 4 of life. Standardized neurodevelopmental assessments were performed at 18-24
months. Unfavorable outcome was defined as death before 2 years of age or severe or moderate disability
at follow-up. Results One hundred and sixty-four of 174 neonates (94%) received TH, of those 30 (18%)
died in the neonatal period (no late mortality). Eighty-one percent of the survivors (109/134) were seen
at 18-24 months. Of the 164 cooled neonates, 62% had a short-term neurological improvement, and the
Sarnat score remained unchanged in 33%. Short-term neurological improvement was associated with
an odds ratio (OR) of 0.118 [95% confidence interval (CI) 0.051-0.271] for an unfavorable outcome at
18-24 months. Conclusion Short-term neurological improvement predicts neurodevelopmental outcome
at 18-24 months in the era of TH. Clinical examination must be part of a comprehensive evaluation for
prognostication in HIE.
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Abstract
Objective: To evaluate the association of short-term neu-
rological improvement until day of life 4 in neonates 
with hypoxic-ischemic encephalopathy (HIE) receiving 
therapeutic hypothermia (TH) with neurodevelopmental 
outcome at 18–24 months.
Methods: This is a retrospective analysis of prospec-
tively collected data of 174 neonates with HIE registered 
in the Swiss National Asphyxia and Cooling Register 
between 2011 and 2013. TH was initiated according to 
national guidelines, and Sarnat staging was performed 
daily. Short-term neurological improvement was defined 
if Sarnat stage improved from admission until day 4 of 
life. Standardized neurodevelopmental assessments 
were performed at 18–24  months. Unfavorable outcome 
was defined as death before 2  years of age or severe or 
 moderate disability at follow-up.
Results: One hundred and sixty-four of 174 neonates (94%) 
received TH, of those 30 (18%) died in the neonatal period 
(no late mortality). Eighty-one percent of the survivors 
(109/134) were seen at 18–24  months. Of the 164 cooled 
neonates, 62% had a short-term neurological improve-
ment, and the Sarnat score remained unchanged in 33%. 
Short-term neurological improvement was associated with 
an odds ratio (OR) of 0.118 [95% confidence interval (CI) 
0.051–0.271] for an unfavorable outcome at 18–24 months.
Conclusion: Short-term neurological improvement 
 predicts neurodevelopmental outcome at 18–24  months 
in the era of TH. Clinical examination must be part of a 
 comprehensive evaluation for prognostication in HIE.
Keywords: hypoxic-ischemic encephalopathy; neuro-
developmental outcome; prognostication.
Introduction
Despite therapeutic hypothermia (TH), up to 50% of neo-
nates with moderate or severe hypoxic-ischemic encepha-
lopathy (HIE) die or suffer from severe neurodevelopmental 
impairment (NDI) [1, 2]. Prediction of expected neurode-
velopmental outcome is crucial during the first few days 
after birth. Different tools to estimate long-term prognosis 
have been studied in the literature and are used for coun-
seling parents (amplitude-integrated electroencephalo-
graphy, conventional electroencephalography, magnetic 
resonance imaging, cranial ultrasound, near-infrared 
spectroscopy, serum biomarkers, placenta  histology). 
The predictive value of these newer imaging and electro-
physiological tools is limited [3, 4]. Additionally, repeated 
clinical examination as one of the earliest tools to evalu-
ate encephalopathy over the first days of life may help to 
estimate prognosis [3, 5, 6].
In 1976, Sarnat and Sarnat evaluated 21 neonates with 
perinatal asphyxia and encephalopathy using a standard-
ized neurological score [7]. In the original Sarnat publi-
cation [7], those neonates with persistent Sarnat stage 3 
until day of life 5 had an unfavorable outcome.
Almost all randomized controlled trials analyzing the 
efficacy of TH for neonates with HIE used Sarnat staging 
as inclusion criteria [1, 2, 8]. However, there is some uncer-
tainty about the significance of clinical examination 
during and after TH and its predictive value [5]. Bonifacio 
et  al. concluded that TH has altered the predictive value 
of severity of encephalopathy on admission [3]. The pre-
dictive ability of the clinical examination shortly after 
rewarming has also changed as neonates with TH and per-
sistent moderate encephalopathy on day 4 still had better 
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neurodevelopmental outcomes compared to neonates 
without TH [3, 5, 6]. After TH has become the standard of 
care, the value of repeated clinical examinations to assess 
the evolution of encephalopathy in TH and its impact 
on neurodevelopmental outcomes after TH has not been 
reported yet.
The aim of this study was to examine the association 
of short-term neurological improvement between admis-
sion and day 4 of life with neurodevelopmental outcome 
at 18–24 months of age in neonates with HIE receiving TH.
Materials and methods
This is a retrospective analysis of prospectively collected data of a 
multicenter cohort study including 174 neonates (≥35 0/7  weeks of 
gestational age) with HIE registered in the Swiss National Asphyxia 
and Cooling Register between 2011 and 2013. TH was initiated within 
6  h of birth at 33.0–34.0 °C core temperature (whole-body cooling 
with ice gel packs or servo coolers) and continued for 72 h according 
to the national guidelines for neonates with HIE published previously 
[9, 10]. Maternal and neonatal demographics, perinatal data, clinical 
presentation and follow-up data were collected from the entries in 
the Swiss National Asphyxia and Cooling Register and amended by 
review of the maternal and neonatal charts as appropriate.
Data collection, evaluation and publication for this study were 
approved by the Swiss Ethical Committee and the Swiss Federal Com-
mission for Privacy Protection in Medical Research. The study is reg-
istered in ClinicalTrials.gov (NCT02800018).
All neonates had clinical examinations according to Sarnat 
staging performed by a senior neonatal consultant on admission and 
within 24, 48, 72 and 96 h of life, respectively [7]. Neurological short-
term improvement was defined if Sarnat stage improved between 
admission and day 4 of life or if the Sarnat score remained 1 through-
out [11].
Neurodevelopmental follow-up assessments were performed 
by pediatric neurologists or developmental pediatricians at 
 18–24 months of age. The assessment consisted of a clinical exami-
nation, a structured neurological assessment (including hearing and 
vision) and a developmental assessment using the Bayley Scales 
of Infant Development, Second Edition (Bayley-2) (n = 20) [12], the 
Bayley Scales of Infant and Toddler Development, Third Edition 
(Bayley-3) (n = 83) [13] or the Griffith Scale (n = 6) [14] according to 
the follow-up center’s guidelines. In order to compare the different 
versions of the Bayley Scales, conversion equations from regres-
sion analysis were applied for a conversion of Bayley-2 to Bayley-3 
according to Jary et al. [15]. The Griffith Score was not converted, as 
suggested by Cirelli et al. [16]. Cerebral palsy [17] was graded accord-
ing to the Gross Motor Function Classification System (GMFCS) of 
 Palisano et al. for children aged ≤2 years [18].
Primary outcome
Outcome was defined according to previously published randomized 
controlled trials, investigating neurodevelopmental outcome at 
 18–24 months [1, 2, 19].
Unfavorable outcome was defined as either:
(i) All deaths before 2 years of age.
(ii) Severe disability, which was defined as any of the following: 
a cognitive or language Bayley-3  score more than 2  standard 
deviation (SD) below the mean score (i.e. <70), a GMFCS grade 
of level 3–5, hearing impairment requiring hearing aids or 
blindness.
(iii) Moderate disability, which was defined as a cognitive or lan-
guage Bayley-3 score of 1–2 SD below the mean score (i.e. 70–84) 
in addition to one or more of the following: a GMFCS grade of 
level 2, hearing impairment with no amplification or a persis-
tent seizure disorder.
Favorable outcome was defined as either:
(iv) Mild disability, which was defined as a cognitive or language 
Bayley-3  score of 70–84 alone, or a cognitive or language 
 Bayley-3  score ≥85 and a GMFCS level 1 or 2, seizure disorder 
(without anti-epileptic medication) or hearing deficit with the 
ability to follow commands without amplification.
(v) Absence of any of the above.
Statistical methods
We investigated the dichotomous outcome (unfavorable vs. favora-
ble) as well as single outcome components. Descriptive statistics 
included mean and SD for the continuous variables, as well as 
number and percentage of total for the categorical variables. In 
a tabulation of descriptive statistics within strata of neurological 
improvement, exploratory P-values were calculated; these were from 
chi-square (χ2) tests, Wilcoxon tests or t-tests, if the risk factors were 
categorical, ordinal or continuous, respectively.
The binary outcome “unfavorable outcome” was addressed with 
logistic regression, and odds ratios (ORs) and corresponding 95% 
confidence intervals (CIs) were estimated. To quantify the associa-
tion with additional risk factors, multiple logistic regression models 
were used. A subgroup analysis of the prevalence of favorable out-
come stratified by Sarnat stage on admission was performed using 
one-sample proportion tests with continuity correction.
Results are reported according to the Strengthening the Report-
ing of Observational Studies in Epidemiology (STROBE) guidelines 
[20]. All analyses were conducted using R [21].
Results
Study population: neonatal data and 
neurodevelopmental assessment at 
18–24 months
Data of 174 neonates with HIE were recorded in the Swiss 
National Asphyxia and Cooling Register between 2011 and 
2013. A flowchart of the study population is provided in 
Figure 1. Ten neonates (6%) with Sarnat stage 1 on admis-
sion received normothermia and did not undergo follow-
up visits. These neonates were excluded from further 
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analysis. Of the 164 included neonates, 158 (96%) were 
scored as Sarnat 2 (126/164; 77%) and Sarnat 3 (32/164; 
19%), and the remaining six (4%) were cooled despite 
being scored Sarnat 1 on admission, based on the clinical 
judgment of the attending neonatologist. Demographic 
neonatal data are given in Table 1. Fifty-five infants (33%) 
were not available for follow-up: 30 (18%) neonatal deaths 
(13 neonates with Sarnat stage 2, 17 neonates with Sarnat 
stage 3 on admission), 18 (11%) infants did not attend 
 follow-up (parental refusal, n = 15; moving countries, 
n = 3) and seven (4%) infants were lost to follow-up.
The primary outcome at 18–24  months could be 
assessed in 133 of 164 infants (81%). Thirty neonatal 
deaths occurred and 103 infants were assessed with 
Bayley-2 (20/103; 19%) or Bayley-3 (83/103; 81%) at 
18–24  months. The information on the 103 infants who 
had neurodevelopmental outcome assessment is pre-
sented in Table 2.
Short-term neurological improvement and 
its association with neurodevelopmental 
outcome at 18–24 months
Of the 164 cooled neonates, 62% (102/164) had a short-
term neurological improvement on the Sarnat score 
during the first 4 days of life. The Sarnat score remained 
unchanged in 33% (54/164) of neonates. No neonate 
showed persistent worsening encephalopathy during the 
first 4 days of life. In eight (5%) neonates, only one Sarnat 
score was assessed during the first 4  days of life; thus, 
these neonates were excluded from further analysis. The 
characteristics of the two groups (short-term neurological 
improvement yes/no) are given in Table 3.
The association of short-term neurological improve-
ment until day of life 4 with neurodevelopmental outcome 
at 18–24 months is shown in Table 3.
Short-term neurological improvement was asso-
ciated with a lower likelihood of an unfavorable 
outcome at 18–24 months (OR 0.118, 95% CI 0.051–0.271, 
P-value < 0.001).
Four out of four neonates (100%, 95% CI 40%–100%) 
with Sarnat stage 1 on admission had a favorable neurode-
velopmental outcome. Seventy-two out of 98 neonates 
(73%) with Sarnat stage 2 on admission had a favorable 
neurodevelopmental outcome (95% CI 63%–82%). In 
neonates with Sarnat stage 3 on admission, 10 out of 31 
Figure 1: Flowchart of the study population.
Table 1: Descriptive statistics for demographic and clinical 
variables, measured at birth and until discharge from NICU.
Demographic variable   Overall
Included neonates, n   164
Male sex, n (%)   95 (57.9)
Outborn, n (%)   133 (81.1)
Gestational age, mean (SD), days   275 (13), i.e. 
39 + 2 weeks
Birth weight, mean (SD), g   3306 (560)
Sentinel eventa, n (%)   60 (36.6)
Cesarean sectionb, n (%)   87 (53.0)
SES scorec, mean (SD)   5.6 (2.2)
Maternal age, mean (SD), years   31.7 (5.1)
Head circumference at birth, mean (SD), cm   34.4 (1.7)
Apgar 1 min, median (IQR)   1 (1.00, 2.00)
Apgar 5 min, median (IQR)   3 (2.00, 5.00)
Apgar 10 min, median (IQR)   5 (3.00, 6.00)
Prolonged resuscitation > 10 min, n (%)   94 (57.3)
Arterial cord pH, mean (SD)   6.91 (0.23)
Lowest pHd, mean (SD)   6.87 (0.18)
Lowest base excessd, mean (SD)   −19.2 (6.3)
Lowest bicarbonated, mean (SD)   12.9 (4.6)
Hypoglycemiae, n (%)   30 (18.3)
Seizures, n (%)   56 (34.1)
Sarnat stage on admission, n (%)
 Sarnat 1   6 (3.7)
 Sarnat 2   126 (76.8)
 Sarnat 3   32 (19.5)
Sarnat score improvement between DOL 1 and 4, n (%)
 No   54 (32.9)
 Yes   102 (62.2)
 NA   8 (4.9)
Neonatal deaths, n (%)   30 (18.3)
DOL, day of life; NA, not available; SD, standard deviation. aIncludes 
placental abruption, uterine rupture, maternal hemorrhage/
shock, cord prolapse and amniotic embolism. bIncludes planned, 
unplanned and emergency cesarean section. cMaternal and paternal 
socioeconomic score (SES), divided by two. SES was calculated 
according to the recommendations of Largo et al. [22]: SES of the 
mother plus SES of the father or one of them doubled if one was 
unknown. dValues from arterial/venous/capillary samples within the 
first 60 min of life. eAt least one single blood glucose measurement 
of <2.5 mmol/L.
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neonates (32%) had a favorable neurodevelopmental 
outcome (95% CI 17%–51%).
If Sarnat stage improvement was taken as a 
short-term marker to predict favorable neurodevelop-
mental outcome at 18–24 months, the sensitivity and spec-
ificity are important quality criteria for this diagnostic 
test [23]. These parameters with 95% CIs are given in 
Table 4.
Discussion
Outcome prediction in neonates with HIE in the era 
of TH might be different than in the pre-cooling era. To 
date, no single clinical tool exists to reliably predict neu-
rodevelopmental outcome in HIE [3, 4]. HIE is a clinical 
diagnosis characterized by a disorder of neurological 
function occurring after perinatal asphyxia. Repeated 
clinical assessment of the severity of encephalopathy is an 
easily accessible, inexpensive and non-invasive bedside 
examination.
We investigated the predictive value of short-term neu-
rological improvement during the first 4 days of life and 
neurodevelopmental outcome at 18–24 months in a mul-
ticenter cohort study including 164 cooled neonates with 
HIE registered in the Swiss National Asphyxia and Cooling 
Register. Our data provide strong evidence for an associa-
tion between short-term neurological improvement until 
day of life 4 and a favorable outcome at 18–24 months of 
age. We showed that if there was a short-term neurological 
improvement on the Sarnat score between admission and 
day of life 4, there was a very low risk of an unfavorable 
outcome at 18–24 months of age. In the prediction model, 
the sensitivity of a favorable outcome after short-term neu-
rological improvement was 63%. Moreover, those without 
early neurological improvement were unlikely to have a 
favorable outcome at 18–24 months, with a specificity of 
83%.
In the original Sarnat publication [7], those neonates 
with persistent Sarnat stage 3 until day of life 5  had an 
unfavorable outcome, compared to those who normalized 
their neurologic examination over time. Previous studies 
investigated the influence of TH on the prognostic value 
of clinical evaluation in HIE [5, 6]. Data of these studies 
confirmed that the evolution of encephalopathy over the 
first days of life predicts neurodevelopmental outcome in 
cooled and non-cooled neonates [5, 6].
A secondary analysis of the National Institute of 
Child Health and Human Development (NICHD) trial on 
TH in HIE [6] recommended the use of the Sarnat score 
at less than 6 h of age for patient selection for TH and the 
Sarnat score at the end of TH as a predictor of neurode-
velopmental outcome at 18  months. Neonates receiving 
TH showed an earlier improvement of encephalopathy 
in the daily assessments compared to normothermic neo-
nates. Similarly, re-analyzed data from the Cool Cap trial 
[24] including TH and normothermia confirmed that less 
severe encephalopathy, more improvement in encepha-
lopathy and treatment with TH itself were associated 
with better neurodevelopmental outcome at 18  months 
[5]. However, they did not have daily Sarnat scores avail-
able for their analysis. Shankaran et al. showed that the 
change in Sarnat stage in serial examinations better pre-
dicted outcome than the Sarnat score on admission in a 
cohort of normothermic and cooled neonates with HIE [6]. 
The studies by Shankaran et al. and Gunn et al. conclude 
that the improvement of encephalopathy during TH is 
associated with a favorable neurodevelopmental outcome 
whereas the deterioration of encephalopathy predicts an 
unfavorable outcome [5, 6].
Table 2: Descriptive statistics for the outcome variables at 
18–24 months for those 103 infants whose follow-up data were 
available.
Outcome variable   Overall
Infants with FU available, n   109, 103 includeda
Age at FU, mean (SD), months   22.63 (3.34)
Head circumference at FU, mean (SD), cm  48.06 (1.80)
Head circumference at FU, mean (SD), 
z-score
  −0.64 (1.45)
Cognitive Bayley-3 score, mean (SD)   106.57 (15.07)
Language Bayley-3 score, mean (SD)   98.79 (17.49)
Motor Bayley-3 score, mean (SD)   98.31 (12.12)
Cerebral palsy, n (%)   6 (5.5)
Seizures, n (%)   3 (2.8)
Severe visual impairment, n (%)   2 (1.8)
Severe hearing impairment, n (%)   2 (1.8)
Outcome category, n (%)
 Normal   73 (67.0)
 Mild NDI   13 (11.9)
 Moderate NDI    5 (4.6)
 Severe NDI    12 (11.0)
 Death (after NICU discharge)    0 (0.0)
 NAa    6 (5.5)
Unfavorable outcomeb, n (%)
 No   86 (78.9)
 Yes   17 (15.6)
 NAa   6 (5.5)
FU, follow-up; NA, not available; NDI, neurodevelopmental 
impairment; SD, standard deviation. aNo standardized follow-up 
assessment available that could have been transformed into 
Bayley-3 scoring (Griffith Scales performed). bUnfavorable outcome: 
moderate or severe disability at FU assessment; death reported 
separately as no deaths occurred after NICU discharge.
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Our study, performed after TH has become the stand-
ard of care, while the two aforementioned studies were 
randomized controlled trials evaluating TH, supports their 
results. Sixty-two percent of the neonates in our study 
cohort had a short-term neurological improvement and 
80% of them had a favorable outcome at 18–24 months of 
age. In the Cool Cap cohort, the short-term improvement of 
encephalopathy in the TH group was calculated to be 33% 
[5]. In the NICHD cohort, Shankaran et  al. [6] described 
short-term neurological improvement in 16–44% and 
reported daily clinical assessment of encephalopathy. 
The different rate of neurological short-term improvement 
in these three cohorts is remarkable, considering that 
Sarnat scoring for grading of encephalopathy was used 
Table 3: Neurological improvement during the first 4 days of life and its association with neonatal characteristics and neurodevelopmental 
outcome at 18–24 months.





Neonatal variables      
n   54   102  
Male sex, n (%)   28 (51.9)   65 (63.7)   0.205
Outborn, n (%)   48 (88.9)   78 (76.5)   0.097
Gestational age, mean (SD), days   274.22 (13.92)   275.69 (11.93)   0.493
Birth weight, mean (SD), g   3243.89 (601.41)   3338.85 (554.74)   0.325
Head circumference at birth, mean (SD), cm   33.92 (1.75)   34.66 (1.64)   0.021
Sentinel eventa, n (%)   21 (38.9)   37 (36.3)   0.883
Caesarean sectionb, n (%)   32 (59.3)   51 (50.0)   0.35
SES scorec, mean (SD)   5.33 (1.34)   5.69 (2.49)   0.403
Maternal age, mean (SD), years   31.87 (5.07)   31.49 (5.15)   0.67
Apgar 1 min, median (IQR)   1.00 (0.00, 2.00)   1.00 (1.00, 2.00)   0.472
Apgar 5 min, median (IQR)   3.00 (2.00, 5.00)   3.00 (3.00, 5.00)   0.202
Apgar 10 min, median (IQR)   4.00 (2.00, 6.00)   5.00 (3.00, 6.00)   0.25
Prolonged resuscitation >10 min, n (%)       0.649
 No   19 (35.2)   43 (42.2)  
 Yes   34 (63.0)   58 (56.9)  
 NA   1 (1.9)   1 (1.0)  
Arterial cord pH, mean (SD)   6.90 (0.18)   6.92 (0.26)   0.772
Lowest pHd, mean (SD)   6.85 (0.20)   6.89 (0.17)   0.186
Lowest base excessd, mean (SD)   −19.78 (6.68)   −18.92 (6.08)   0.481
Lowest bicarbonated, mean (SD)   11.54 (4.59)   13.70 (4.53)   0.027
Sarnat score on admission, n (%)       0.023
 Sarnat 1   0 (0.0)   6 (5.9)  
 Sarnat 2   38 (70.4)   81 (79.4)  
 Sarnat 3   16 (29.6)   15 (14.7)  
Hypoglycemiae, n (%)   13 (24.1)   16 (15.7)   0.287
Seizures, n (%)   31 (57.4)   24 (23.5)   <0.001
Neonatal deaths, n (%)   27 (50.0)   3 (2.9)   <0.001
Follow-up variables      
Head circumference at FU, mean (SD), cm   47.92 (2.23)   48.10 (1.67)   0.705
Head circumference at FU, mean (SD), 
z-score
  −0.74 (1.91)   −0.64 (1.34)   0.8
Cognitive Bayley-3 score >85, n (%)   15 (27.8)   72 (70.6)   <0.001
Language Bayley-3 score >85, n (%)   14 (25.9)   56 (54.9)   <0.001
Motor Bayley-3 score >85, n (%)   15 (27.8)   70 (68.6)   <0.001
Descriptive statistics of the risk factors at birth and neurodevelopmental outcome at 18–24 months, stratified by short-term improvement 
(i.e. Sarnat score improvement between admission and day of life 4). Descriptive statistics of these variables are displayed together with 
exploratory P-values from χ2 tests (for categorical variables) as well as Wilcoxon tests (for ordinal variables) and t-tests (for continuous 
variables). If medians and interquartile ranges (IQR) are given as summary measure, the variable was considered ordinal. aIncludes 
placental abruption, uterine rupture, maternal hemorrhage/shock, cord prolapse and amniotic embolism. bIncludes planned, unplanned 
and emergency cesarean section. cMaternal and paternal socioeconomic score (SES), divided by two. SES was calculated according to the 
recommendations of Largo et al. [22]: SES of the mother plus SES of the father or one of them doubled if one was unknown. dValues from 
arterial/venous/capillary samples within the first 60 min of life. eAt least one single blood glucose measurement of <2.5 mmol/L.
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in all three studies. Probably, this is related to a gain in 
experience in performing Sarnat scoring in cooled neo-
nates or the overall improved management of cooled neo-
nates with HIE during the last few years due to increasing 
experience. In contrast to other studies [5, 6], there was 
no worsening encephalopathy in our cohort. This might 
be explained by the fact that we classified neonates with 
the trajectory of any neurological improvement between 
admission and day of life 4 as improvement and did not 
account for intermittent worsening of encephalopathy if 
followed by later improvement compared to Sarnat stage 
on admission. Notably, those eight neonates with only 
one single Sarnat scoring on admission in our cohort all 
survived, which makes worsening encephalopathy also 
highly unlikely.
The clinical presentation of our study population was 
similar to that of previously published HIE cohorts.
There was no late mortality after discharge from 
the neonatal intensive care unit (NICU). Early neona-
tal deaths were mainly due to redirection of care if very 
unfavorable outcome was expected. We applied the same 
criteria for favorable and unfavorable outcomes as used 
in the  randomized controlled trials on TH [1, 2]. However, 
in accordance with more recently published studies [19], 
we used Bayley-3 assessments at 18–24 months (instead of 
Bayley-2) as Bayley-3 is established as a standard test now-
adays. We used the cut-off values for Bayley-3 to define 
mild/moderate/severe disability as suggested by Laptook 
et al. [19]. We reached a high follow-up rate of 81% (of the 
survivors) at the age of 18–24  months and children will 
further be followed-up until school age.
The generalizability of our results is limited due to the 
relatively small sample size. We focused on the predic-
tive strength of clinical examinations (daily Sarnat score) 
with almost no missing data in the National Asphyxia 
and Cooling Register [10]. Therefore, the evolution of 
encephalopathy during TH is a valuable clinical outcome 
predictor in our setting. However, we did not account 
for the interrater reliability (between cooling centers) 
in Sarnat scoring. We did not include cerebral magnetic 
resonance imaging findings. After the implementation 
of the National Asphyxia and Cooling Register, cerebral 
magnetic resonance imaging assessment after rewarming 
is increasingly performed nowadays, but in no more than 
62% of neonates with TH in 2011–2012 [10]. There were 
inconsistent data on electroencephalography recordings 
and anti-epileptic medication and thus this risk factor 
could not be analyzed. Furthermore, we were not able to 
collect data on inter-current illnesses between discharge 
from NICU and follow-up assessment. Inter-current illness 
including prolonged hospitalization might worsen neu-
rodevelopmental outcome independent of HIE. Neurode-
velopmental interventions to mitigate impairment also 
were not reported.
Clinical examination to assess encephalopathy for 
outcome prediction remains a meaningful, easily acces-
sible, inexpensive and non-invasive bedside tool in the 
era of magnetic resonance imaging and electrographical 
monitoring for neonates who are treated with TH for HIE. 
Obviously, in high-income countries, counseling parents 
relies on a comprehensive evaluation of the available 
clinical, electrographical and neuro-imaging data. The 
results of our study show that a detailed and serial clinical 
neurological examination during TH for HIE can provide 
valid outcome prediction abilities. Therefore, teaching 
clinical neurological examination skills to younger col-
leagues is of highest importance to maintain the expertise 
of  assessing neonates with encephalopathy.
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Sensitivity   0.64   0.49   0.77
Specificity   0.83   0.73   0.9
PPV   0.68   0.52   0.81
NPV   0.80   0.7   0.88
Evaluation of short-term neurological improvement (measured 
with the Sarnat score) as a diagnostic test for favorable 
neurodevelopmental outcome at 18–24 months. CI, confidence 
interval; PPV, positive predictive value; NPV, negative predictive 
value.
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